{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:41:14Z","timestamp":1776418874717,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["006.18"],"award-info":[{"award-number":["006.18"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SIDN fund","award":["174054"],"award-info":[{"award-number":["174054"]}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["003-2018"],"award-info":[{"award-number":["003-2018"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["VIDI198.007"],"award-info":[{"award-number":["VIDI198.007"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Treatment with the tyrosine kinase inhibitor (TKI) imatinib in patients with gastrointestinal stromal tumours (GIST) causes symptoms that could negatively impact health-related quality of life (HRQoL). Treatment-related symptoms are usually clinician-reported and little is known about patient reports. We used survey and online patient forum data to investigate (1) prevalence of patient-reported symptoms; (2) coverage of symptoms mentioned on the forum by existing HRQoL questionnaires; and (3) priorities of prevalent symptoms in HRQoL assessment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the cross-sectional population-based survey study, Dutch GIST patients completed items from the EORTC QLQ-C30 and Symptom-Based Questionnaire (SBQ). In the forum study, machine learning algorithms were used to extract TKI side-effects from English messages on an international online forum for GIST patients. Prevalence of symptoms related to imatinib treatment in both sources was calculated and exploratively compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fatigue and muscle pain or cramps were reported most frequently. Seven out of 10 most reported symptoms (i.e. fatigue, muscle pain or cramps, facial swelling, joint pain, skin problems, diarrhoea, and oedema) overlapped between the two sources. Alopecia was frequently mentioned on the forum, but not in the survey. Four out of 10 most reported symptoms on the online forum are covered by the EORTC QLQ-C30. The EORTC-SBQ and EORTC Item Library cover 9 and 10 symptoms, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This first overview of patient-reported imatinib-related symptoms from two data sources helps to determine coverage of items in existing questionnaires, and prioritize HRQoL issues. Combining cancer-generic instruments with treatment-specific item lists will improve future HRQoL assessment in care and research in GIST patients using TKI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-022-06929-3","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T03:02:46Z","timestamp":1646190166000},"page":"5137-5146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data"],"prefix":"10.1007","volume":"30","author":[{"given":"Dide","family":"den Hollander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne R.","family":"Dirkson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan","family":"Verberne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wessel","family":"Kraaij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"van Oortmerssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Oosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K. L.","family":"Reyners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winette T. A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid M. E.","family":"Desar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-8686","authenticated-orcid":false,"given":"Olga","family":"Husson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"6929_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K S\u00f8reide","year":"2016","unstructured":"S\u00f8reide K, Sandvik OM, S\u00f8reide JA, Giljaca V, Jureckova A, Bulusu VR (2016) Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol 40:39\u201346. https:\/\/doi.org\/10.1016\/j.canep.2015.10.031","journal-title":"Cancer Epidemiol"},{"issue":"36","key":"6929_CR2","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1200\/jco.2015.62.4304","volume":"33","author":"PG Casali","year":"2015","unstructured":"Casali PG, Le Cesne A, Poveda Velasco A et al (2015) Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33(36):4276\u20134283. https:\/\/doi.org\/10.1200\/jco.2015.62.4304","journal-title":"J Clin Oncol"},{"issue":"7","key":"6929_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472\u2013480. https:\/\/doi.org\/10.1056\/NEJMoa020461","journal-title":"N Engl J Med"},{"issue":"11","key":"6929_CR4","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1158\/1078-0432.Ccr-11-3005","volume":"18","author":"GD Demetri","year":"2012","unstructured":"Demetri GD, Garrett CR, Sch\u00f6ffski P et al (2012) Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 18(11):3170\u20133179. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-3005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6929_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/107327480501200106","volume":"12","author":"G D\u2019Amato","year":"2005","unstructured":"D\u2019Amato G, Steinert DM, McAuliffe JC, Trent JC (2005) Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 12(1):44\u201356. https:\/\/doi.org\/10.1177\/107327480501200106","journal-title":"Cancer Control"},{"issue":"4","key":"6929_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/jco.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620\u2013625. https:\/\/doi.org\/10.1200\/jco.2007.13.4403","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"6929_CR7","doi-asserted-by":"publisher","first-page":"iv68","DOI":"10.1093\/annonc\/mdy095","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, Abecassis N, Aro HT et al (2018) Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv68\u2013iv78. https:\/\/doi.org\/10.1093\/annonc\/mdy095","journal-title":"Ann Oncol"},{"issue":"1","key":"6929_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ctrv.2010.04.008","volume":"37","author":"H Joensuu","year":"2011","unstructured":"Joensuu H, Trent JC, Reichardt P (2011) Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 37(1):75\u201388. https:\/\/doi.org\/10.1016\/j.ctrv.2010.04.008","journal-title":"Cancer Treat Rev"},{"key":"6929_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-4-79","volume":"4","author":"U.S. Department of Health and Human Services FDA for Drug Evaluation and Research","year":"2006","unstructured":"U.S. Department of Health and Human Services FDA for Drug Evaluation and Research (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79. https:\/\/doi.org\/10.1186\/1477-7525-4-79","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"6929_CR10","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","volume":"24","author":"TM Atkinson","year":"2016","unstructured":"Atkinson TM, Ryan SJ, Bennett AV et al (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24(8):3669\u20133676. https:\/\/doi.org\/10.1007\/s00520-016-3297-9","journal-title":"Support Care Cancer"},{"issue":"5","key":"6929_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","volume":"13","author":"M Di Maio","year":"2016","unstructured":"Di Maio M, Basch E, Bryce J, Perrone F (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 13(5):319\u2013325. https:\/\/doi.org\/10.1038\/nrclinonc.2015.222","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"6929_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1177\/1049732309354094","volume":"20","author":"C Seale","year":"2010","unstructured":"Seale C, Charteris-Black J, MacFarlane A, McPherson A (2010) Interviews and internet forums: a comparison of two sources of qualitative data. Qual Health Res 20(5):595\u2013606. https:\/\/doi.org\/10.1177\/1049732309354094","journal-title":"Qual Health Res"},{"issue":"5","key":"6929_CR13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1177\/104973201129119398","volume":"11","author":"KM Robinson","year":"2001","unstructured":"Robinson KM (2001) Unsolicited narratives from the Internet: a rich source of qualitative data. Qual Health Res 11(5):706\u2013714. https:\/\/doi.org\/10.1177\/104973201129119398","journal-title":"Qual Health Res"},{"issue":"4","key":"6929_CR14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bcp.12746","volume":"80","author":"S Golder","year":"2015","unstructured":"Golder S, Norman G, Loke YK (2015) Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br J Clin Pharmacol 80(4):878\u2013888. https:\/\/doi.org\/10.1111\/bcp.12746","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"6929_CR15","doi-asserted-by":"publisher","DOI":"10.2196\/medinform.7779","volume":"5","author":"MD Tapi Nzali","year":"2017","unstructured":"Tapi Nzali MD, Bringay S, Lavergne C, Mollevi C, Opitz T (2017) What patients can tell us: topic analysis for social media on breast cancer. JMIR Med Inform 5(3):e23. https:\/\/doi.org\/10.2196\/medinform.7779","journal-title":"JMIR Med Inform"},{"issue":"1","key":"6929_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11523-020-00769-z","volume":"16","author":"SC Sodergren","year":"2021","unstructured":"Sodergren SC, Wheelwright SJ, Fitzsimmons D et al (2021) Developing symptom lists for people with cancer treated with targeted therapies. Target Oncol 16(1):95\u2013107. https:\/\/doi.org\/10.1007\/s11523-020-00769-z","journal-title":"Target Oncol"},{"key":"6929_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13569-019-0116-3","volume":"9","author":"L Fauske","year":"2019","unstructured":"Fauske L, Hompland I, Lorem G, Bondevik H, Bruland OS (2019) Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study. Clin Sarcoma Res 9:6. https:\/\/doi.org\/10.1186\/s13569-019-0116-3","journal-title":"Clin Sarcoma Res"},{"issue":"2","key":"6929_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpainsymman.2016.02.019","volume":"52","author":"H Poort","year":"2016","unstructured":"Poort H, van der Graaf WT, Tielen R et al (2016) Prevalence, impact, and correlates of severe fatigue in patients with gastrointestinal stromal tumors. J Pain Symptom Manage 52(2):265\u2013271. https:\/\/doi.org\/10.1016\/j.jpainsymman.2016.02.019","journal-title":"J Pain Symptom Manage"},{"issue":"8","key":"6929_CR19","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3109\/0284186x.2014.1003960","volume":"54","author":"JA Custers","year":"2015","unstructured":"Custers JA, Tielen R, Prins JB, de Wilt JH, Gielissen MF, van der Graaf WT (2015) Fear of progression in patients with gastrointestinal stromal tumors (GIST): is extended lifetime related to the Sword of Damocles? Acta Oncol 54(8):1202\u20131208. https:\/\/doi.org\/10.3109\/0284186x.2014.1003960","journal-title":"Acta Oncol"},{"issue":"6","key":"6929_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473\u2013483","journal-title":"Med Care"},{"issue":"5","key":"6929_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6929_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1155\/2007\/971816","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M, Tiebosch AT, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29(1):19\u201324. https:\/\/doi.org\/10.1155\/2007\/971816","journal-title":"Cell Oncol"},{"key":"6929_CR23","unstructured":"GIST Support International (2002) https:\/\/www.gistsupport.org\/ Accessed on 7 July 2021"},{"issue":"14","key":"6929_CR24","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","volume":"47","author":"LV van de Poll-Franse","year":"2011","unstructured":"van de Poll-Franse LV, Horevoorts N, van Eenbergen M et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188\u20132194. https:\/\/doi.org\/10.1016\/j.ejca.2011.04.034","journal-title":"Eur J Cancer"},{"key":"6929_CR25","unstructured":"Dirkson AR, Verberne S, Kraaij W, van Oortmerssen G, Gelderblom H (2021) Automatic extraction of patient-reported adverse drug events from a GIST patient forum. Connective Tissue Oncology Society Annual Meeting (27):P059"},{"key":"6929_CR26","unstructured":"Johnson CD, Aaronson NK, Blazeby J et al (2011) Guidelines for Developing Questionnaire Modules 4th Edition. European Organisation for Research and Treatment of Cancer. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/guidelines_for_developing_questionnaire-_final.pdf. Accessed on 8 Jan 2020"},{"issue":"1","key":"6929_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.critrevonc.2014.01.002","volume":"91","author":"SC Sodergren","year":"2014","unstructured":"Sodergren SC, White A, Efficace F et al (2014) Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Crit Rev Oncol Hematol 91(1):35\u201346. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.01.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"6929_CR28","unstructured":"Dirkson AR (2021) Automatic extraction of patient-reported adverse drug events from a GIST patient forum. Heroku. https:\/\/dashboard-gist-adr.herokuapp.com\/. Accessed on 14 July 2021"},{"issue":"2","key":"6929_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/art.10993","volume":"49","author":"O Sangha","year":"2003","unstructured":"Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156\u2013163. https:\/\/doi.org\/10.1002\/art.10993","journal-title":"Arthritis Rheum"},{"issue":"23","key":"6929_CR30","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/jnci\/djp386","volume":"101","author":"E Basch","year":"2009","unstructured":"Basch E, Jia X, Heller G et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624\u20131632. https:\/\/doi.org\/10.1093\/jnci\/djp386","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"6929_CR31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3324\/haematol.2013.093724","volume":"99","author":"F Efficace","year":"2014","unstructured":"Efficace F, Rosti G, Aaronson N et al (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99(4):788\u2013793. https:\/\/doi.org\/10.3324\/haematol.2013.093724","journal-title":"Haematologica"},{"key":"6929_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-020-01866-3","author":"EB Carbajal-L\u00f3pez","year":"2020","unstructured":"Carbajal-L\u00f3pez EB, Ju\u00e1rez-Garc\u00eda DM, Espinoza-Velazco A, Calderillo-Ruiz G (2020) Internet-delivered cognitive behavioral therapy and psychoeducation program for patients with gastrointestinal stromal tumors. J Cancer Educ. https:\/\/doi.org\/10.1007\/s13187-020-01866-3","journal-title":"J Cancer Educ"},{"key":"6929_CR33","doi-asserted-by":"publisher","unstructured":"Williams LA, Araujo DM, Shi Q et al (2014) Symptoms in gastrointestinal stromal tumors. J Clin Oncol 32(5s). https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.9637","DOI":"10.1200\/jco.2014.32.15_suppl.9637"},{"issue":"6","key":"6929_CR34","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/j.leukres.2010.11.028","volume":"35","author":"S Mariani","year":"2011","unstructured":"Mariani S, Abruzzese E, Basciani S et al (2011) Reversible hair depigmentation in a patient treated with imatinib. Leuk Res 35(6):e64-66. https:\/\/doi.org\/10.1016\/j.leukres.2010.11.028","journal-title":"Leuk Res"},{"key":"6929_CR35","doi-asserted-by":"publisher","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 72(2): 203\u2013218; quiz 219\u2013220. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.032","DOI":"10.1016\/j.jaad.2014.07.032"},{"key":"6929_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2021.06.025","author":"GI Ector","year":"2021","unstructured":"Ector GI, Verweij L, Hermens RP, Blijlevens NM (2021) Filling the gaps of patient information needs and information perception in chronic myeloid leukemia with the patient-physician co-produced web-based platform CMyLife. Patient Educ Couns. https:\/\/doi.org\/10.1016\/j.pec.2021.06.025","journal-title":"Patient Educ Couns"},{"issue":"2","key":"6929_CR37","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.992","volume":"10","author":"CF van Uden-Kraan","year":"2008","unstructured":"van Uden-Kraan CF, Drossaert CH, Taal E, Seydel ER, van de Laar MA (2008) Self-reported differences in empowerment between lurkers and posters in online patient support groups. J Med Internet Res 10(2):e18. https:\/\/doi.org\/10.2196\/jmir.992","journal-title":"J Med Internet Res"},{"issue":"7","key":"6929_CR38","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/0002764217717559","volume":"61","author":"G Blank","year":"2017","unstructured":"Blank G, Lutz C (2017) Representativeness of social media in Great Britain: investigating Facebook, LinkedIn, Twitter, Pinterest, Google+, and Instagram. Am Behav Sci 61(7):741\u2013756. https:\/\/doi.org\/10.1177\/0002764217717559","journal-title":"Am Behav Sci"},{"issue":"1","key":"6929_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/0894439318788322","volume":"38","author":"E Hargittai","year":"2020","unstructured":"Hargittai E (2020) Potential biases in big data: omitted voices on social media. Soc Sci Comput Rev 38(1):10\u201324. https:\/\/doi.org\/10.1177\/0894439318788322","journal-title":"Soc Sci Comput Rev"},{"issue":"1","key":"6929_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11764-020-00913-8","volume":"15","author":"N Fareed","year":"2021","unstructured":"Fareed N, Swoboda CM, Jonnalagadda P, Huerta TR (2021) Persistent digital divide in health-related internet use among cancer survivors: findings from the Health Information National Trends Survey, 2003\u20132018. J Cancer Surviv 15(1):87\u201398. https:\/\/doi.org\/10.1007\/s11764-020-00913-8","journal-title":"J Cancer Surviv"},{"issue":"7","key":"6929_CR41","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.Ccr-15-2035","volume":"22","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Slagle A, Papadopoulos EJ et al (2016) Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res 22(7):1553\u20131558. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2035","journal-title":"Clin Cancer Res"},{"key":"6929_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2019.08.016","volume":"121","author":"A Bottomley","year":"2019","unstructured":"Bottomley A, Reijneveld JC, Koller M, Flechtner H, Tomaszewski KA, Greimel E (2019) Current state of quality of life and patient-reported outcomes research. Eur J Cancer 121:55\u201363. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.016","journal-title":"Eur J Cancer"},{"key":"6929_CR43","doi-asserted-by":"crossref","unstructured":"Kuli\u015b D, Whittaker C, van de Poll-Franse LV et al (2017) The use of the EORTC Item Library to supplement EORTC quality of life instruments. Value in Health ISPOR 20th Annual European Congress. (20):A775","DOI":"10.1016\/j.jval.2017.08.2236"},{"key":"6929_CR44","doi-asserted-by":"publisher","unstructured":"Basch E, Reeve BB, Mitchell SA et al (2014) Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106 (9):dju244. https:\/\/doi.org\/10.1093\/jnci\/dju244","DOI":"10.1093\/jnci\/dju244"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06929-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T10:50:14Z","timestamp":1651056614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06929-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6929"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06929-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the cross-sectional study was provided by the medical ethical committee of the Radboud University Medical Centre (2019\u20135888). According to the Dutch law, approval of one ethical committee for questionnaire research is valid for all participating centres. Permission to use data from the Facebook group was given by GIST Support International. Discussions were pseudonymized and messages could not be traced back to individual members. No formal approval was needed for the use of data from the public Facebook group, as the General Data Protection Regulation (GDPR) allows the use of data from publicly accessible forums with justified cause.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"In the survey study, participants provided informed consent, including permission to link survey data with data from the NCR. Permission to use data from the Facebook group was given by GIST Support International.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}